10.23.14
Alexion
3Q Revenues: $555.1 million (+39%)
3Q Earnings: $177.7 million (+89%)
YTD Revenues: $1.6 billion (+48%)
YTD Earnings: $503.6 million (+85%)
Comments: Soliris sales were $555.1 million in the quarter, up 39%, driven by steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) commencing Soliris treatment. R&D expenses were $100.7 million in the quarter, up 14%.
3Q Revenues: $555.1 million (+39%)
3Q Earnings: $177.7 million (+89%)
YTD Revenues: $1.6 billion (+48%)
YTD Earnings: $503.6 million (+85%)
Comments: Soliris sales were $555.1 million in the quarter, up 39%, driven by steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) commencing Soliris treatment. R&D expenses were $100.7 million in the quarter, up 14%.